Efficacy and vitreous levels of topical NSAIDs

Bibliography

• Barba KR, Samy A, Lai C, et al. Effect of topical anti-inflammatory drugs on corneal and limbal wound healing. J Cataract Refract Surg 2000;26(6):893-7
   PubMed Web of Science ®Google Scholar
• Russo A, Costagliola C, Delcassi L, et al. Topical nonsteroidal anti-inflammatory drugs for macular edema. Mediators Inflamm 2013;2013:476525
   PubMed Web of Science ®Google Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55(2):108-33
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflamm 2013;2013:281981
   PubMedGoogle Scholar
• Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 2005;11(5):1999-2007
   PubMed Web of Science ®Google Scholar
• Chin MS, Nagineni CN, Hooper LC, et al. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001;42(10):2338-46
   PubMed Web of Science ®Google Scholar
• Chang JH, Chung H. Non-steroidal anti-inflammatory drug and endotoxin induced uveitis. Korean J Ophthalmol 1993;7(2):35-42
   PubMedGoogle Scholar
• Costagliola C, Parmeggiani F, Caccavale A, et al. Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma. Am J Ophthalmol 2006;141(2):379-81
   PubMed Web of Science ®Google Scholar
• Costagliola C, Parmeggiani F, Antinozzi PP, et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res 2005;81(5):610-15
   PubMed Web of Science ®Google Scholar
• Grob SR, Gonzalez-Gonzalez LA, Daly MK. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Clin Ophthalmol 2014;8:1281-9
   PubMedGoogle Scholar
• Shinomiya S, Naraba H, Ueno A, et al. Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol 2001;61(9):1153-60
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, et al. Topical ocular delivery of NSAIDs. AAPS J 2008;10(2):229-41
   PubMed Web of Science ®Google Scholar
• Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000;24(4):357-70
   PubMed Web of Science ®Google Scholar
• Kida T, Kozai S, Takahashi H, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One 2014;9(5):e96481
   PubMed Web of Science ®Google Scholar
• Januleviciene I, Siaudvytyte L, Barsauskaite R. Ophthalmic drug delivery in glaucoma-a review. Pharmaceutics 2012;4(1):243-51
   PubMedGoogle Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217(2):89-98
   PubMed Web of Science ®Google Scholar
• Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24(4):371-84
   PubMed Web of Science ®Google Scholar
• Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother 2009;10(14):2379-85
   PubMed Web of Science ®Google Scholar
• Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008;24(4):392-8
   PubMed Web of Science ®Google Scholar
• Lane SS. Nepafenac: a unique nonsteroidal prodrug. Int Ophthalmol Clin 2006;46(4):13-20
   PubMedGoogle Scholar
• Jones BM, Neville MW. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann Pharmacother 2013;47(6):892-6
   PubMed Web of Science ®Google Scholar
• Sandoval HP, De Castro LEF, Vroman DT, et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther 2006;22(4):251-7
   PubMed Web of Science ®Google Scholar
• Walters T, Raizman M, Enìrnest P, et al. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, an bromfenac. J Cataract Refract Surg 2007;33(9):1539-45
   PubMed Web of Science ®Google Scholar
• Bucolo C, Melilli B, Piazza C, et al. Ocular pharmacokinetics profile of different indomethacin topical formulations. J Ocul Pharmacol Ther 2011;27(6):571-6
   PubMed Web of Science ®Google Scholar
• Blaydes JE, Kelley EP, Walt JG, et al. Flurbiprofen 0.03% for the control of inflammation following cataract extraction by phacoemulsification. J Cataract Refract Surg 1993;19(4):481-7
   PubMed Web of Science ®Google Scholar
• Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg 1996;22 Suppl 1:780-7
   PubMed Web of Science ®Google Scholar
• Solomon KD, Turkalj JW, Whiteside SB, et al. Topical 0.5% ketorolac vs 0.03% flurbiprofen for inhibition of miosis during cataract surgery. Arch Ophthalmol 1997;115(9):1119-22
   PubMed Web of Science ®Google Scholar
• Bucci FA, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol 2007;144(1):146-7
   PubMed Web of Science ®Google Scholar
• Naveh N, Weissman C. The correlation between excessive vitreal protein levels, prostaglandin E2 levels, and the blood retinal barrier. Prostaglandins 1990;39(2):147-56
   PubMed Web of Science ®Google Scholar
• Yanni SE, McCollum GW, Penn JS. Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Exp Eye Res 2010;91(1):34-41
   PubMed Web of Science ®Google Scholar
• Cheng T, Cao W, Wen R, et al. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci 1998;39(3):581-91
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ, Sheng J, et al. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. JAMA Ophthalmol 2014;132(2):150-4
   Web of Science ®Google Scholar
• Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina 2009;29(9):1310-13
   PubMed Web of Science ®Google Scholar
• Morescalchi F, Duse S, Gambicorti E, et al. Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid. Mediators Inflamm 2013;2013:269787
   PubMed Web of Science ®Google Scholar
• Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidine-purite 0.15%. J Ocul PharmacolTher 2006;22(4):242-6
   Google Scholar
• Russo A. Vitreous Nonsteroidal Anti-Inflammatory Drug Levels in Vitrectomy Patients Treated with Topical Indomethacin 0.5%, Nepafenac 0.1%, and Bromfenac 0.09%. University of Brescia, Italy, ARVO; Denver, USA: 2015
   Google Scholar
• Hughes PM, Olejnik O, Chang-Lin JE, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005;57(14):2010-32
   PubMed Web of Science ®Google Scholar
• Sieg JW, Robinson JR. Mechanistic studies on trans-corneal permeation of pilocarpine. J Pharm Sci 1976;65:1816-20
   PubMed Web of Science ®Google Scholar
• Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF. Penetration into the anterior chamber via the conjunctival/scleral pathway. J Ocular Pharmacol Ther 1997;13(1):41-59
   PubMed Web of Science ®Google Scholar
• Rho DS. Treatment of acute pseudophakic cystoi macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29(12):2378-84
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 1999;97(3-4):297-309
   PubMed Web of Science ®Google Scholar
• Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 1998;96:557-634
   PubMedGoogle Scholar
• Yilmaz T, Cordero-Coma M, Gallagher MJ. Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye (Lond) 2012;26(2):252-8
   PubMed Web of Science ®Google Scholar
• Ticly FG, Lira RPC, Zanetti FR, et al. Prophylactic use of ketorolac tromethamine in cataract surgery: a randomized trial. J Ocul Pharmacol Ther 2014;30(6):495-501
   PubMed Web of Science ®Google Scholar
• Bucci FA, Waterbury LD. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin 2011;27(12):2235-9
   PubMed Web of Science ®Google Scholar
• Weber M, Kodjikian L, Kruse FE, et al. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmol 2013;91(1):e15-21
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Akduman L, Clever JA, et al. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clin Ophthalmol 2009;3:147-54
   PubMedGoogle Scholar
• Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30(2):260-6
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005;89(11):1420-2
   PubMed Web of Science ®Google Scholar
• Kessel L, Tendal B, Jørgensen KJ, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology 2014;121(10):1915-24
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114(9):1653-62
   PubMed Web of Science ®Google Scholar
• Colak E, Majkic-Singh N, Zoric L, et al. The role of CRP and inflammation in the pathogenesis of age-related macular degeneration. Biochem Medica 2012;22(1):39-48
   PubMed Web of Science ®Google Scholar
• Parmeggiani F, Romano MR, Costagliola C, et al. Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm 2012;2012:546786
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454(7203):428-35
   PubMed Web of Science ®Google Scholar
• Nita M, Grzybowski A, Ascaso FJ, et al. Age-related macular degeneration in the aspect of chronic low-grade inflammation (pathophysiological parainflammation). Mediators Inflamm 2014;2014:930671
   PubMed Web of Science ®Google Scholar
• Machalińska A, Dziedziejko V, Mozolewska-Piotrowska K, et al. Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 2009;42(1):54-9
   PubMed Web of Science ®Google Scholar
• Reynolds R, Hartnett ME, Atkinson JP, et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009;50(12):5818-27
   PubMed Web of Science ®Google Scholar
• Libondi T, Jonas JB. Topical nepafenac for treatment of exudative age-related macular degeneration. Acta Ophthalmol 2010;88(2):e32-3
   PubMed Web of Science ®Google Scholar
• Chen E, Benz MS, Fish RH, et al. Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol 2010;4:1249-52
   PubMedGoogle Scholar
• Parmeggiani F, Sorrentino FS, Romano MR, et al. Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks. Mediators Inflamm 2013;2013:435607
   PubMed Web of Science ®Google Scholar
• McGeer PL, Sibley J. Sparing of age-related macular degeneration in rheumatoid arthritis. Neurobiol Aging 2005;26(8):1199-203
   PubMed Web of Science ®Google Scholar
• Wilson HL, Schwartz DM, Bhatt HRF, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004;137(4):615-24
   PubMed Web of Science ®Google Scholar
• Penfold PL, Provis JM, Furby JH, et al. Autoantibodies to retinal astrocytes associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1990;228(3):270-4
   PubMed Web of Science ®Google Scholar
• Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem 2003;278(43):42027-35
   PubMed Web of Science ®Google Scholar
• Rezaei KA, Toma HS, Cai J, et al. Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice. Invest Ophthalmol Vis Sci 2011;52(2):701-7
   PubMed Web of Science ®Google Scholar
• Yoshinaga N, Arimura N, Otsuka H, et al. NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab Investig 2011;91(9):1277-90
   PubMed Web of Science ®Google Scholar
• Grant CA. Combination therapy: lucentis (ranibizumab injection) and xibrom (bromfenac ophthalmic solution) 0.09% in the treatment of choroidal neovascular membrane secondary to age-related macular degeneration. 2008;49:E-Abstract 563
   Google Scholar
• Flaxel C, Schain MB, Hamon SC, et al. Prospective randomized controlled trial of combination ranibizumab (lucentis) and bromfenac (xibrom) for neovascular age-related macular degeneration: a Pilot Study. Retina 2012;32(3):417-23
   PubMed Web of Science ®Google Scholar
• Gomi F, Sawa M, Tsujikawa M, et al. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 2012;32(9):1804-10
   PubMed Web of Science ®Google Scholar
• Russo A, Costagliola C, Delcassi L, et al. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration. Br J Ophthalmol 2013;97(10):1273-6
   PubMed Web of Science ®Google Scholar
• Semeraro F, Russo A, Delcassi L, et al. Treatment of exudative age-related macular degeneration with ranibizumab combined with ketorolac eyedrops or photodynamic therapy. Retina 2015. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Shin HJ, Chung H, Kim HC. Association between foveal microstructure and visual outcome in age-related macular degeneration. Retina 2011;31(8):1627-36
   PubMed Web of Science ®Google Scholar
• Zweifel SA, Engelbert M, Khan S, et al. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009;29(10):1527-31
   PubMed Web of Science ®Google Scholar
• Wyględowska-Promieńska D, Piotrowska-Gwóźdź A, Piotrowska-Seweryn A, et al. Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study. Med Sci Monit 2014;20:1168-75
   PubMedGoogle Scholar
• Ulrich JN. Topical nepafenac after intravitreal injection: a prospective double-masked randomized controlled trial. Retina 2014;34(3):509-11
   PubMed Web of Science ®Google Scholar
• Georgakopoulos CD, Vasilakis PT, Makri OE, et al. Effect of ketorolac 0.5% drops on patients’ pain perception during intravitreal injection procedure. J Ocul Pharmacol Ther 2012;28(5):455-8
   PubMed Web of Science ®Google Scholar
• Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30(5):343-58
   PubMed Web of Science ®Google Scholar
• Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol 2012;19(1):52-9
   PubMedGoogle Scholar
• Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol 2009;147(1):11-21.e1
   PubMed Web of Science ®Google Scholar
• Lange CAK, Stavrakas P, Luhmann UFO, et al. Intraocular oxygen distribution in advanced proliferative diabetic retinopathy. Am J Ophthalmol 2011;152(3):406-12; e3
   PubMed Web of Science ®Google Scholar
• Rezzola S, Monte MD, Belleri M, et al. Therapeutic potential of anti-angiogenic multi-target N,O-sulfated E. Coli K5 polysaccharide in diabetic retinopathy. Diabetes 2015;64(7):2581-92
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 2011;55(3):256-63
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res 2012;37(5):416-20
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ, Sheng J, et al. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci 2012;53(9):5906-11
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16(3):438-40
   PubMed Web of Science ®Google Scholar
• Limb GA, Chignell AH, Green W, et al. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 1996;80(2):168-73
   PubMed Web of Science ®Google Scholar
• Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006;20(12):1366-9
   PubMed Web of Science ®Google Scholar
• Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007;56(1):224-30
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Odenbach S. Role of interleukin-1beta in the development of retinopathy in rats: effect of antioxidants. Invest Ophthalmol Vis Sci 2004;45(11):4161-6
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003;110(9):1690-6
   PubMed Web of Science ®Google Scholar
• Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001;15(5):257-9
   PubMed Web of Science ®Google Scholar
• Meleth AD, Agrón E, Chan C-C, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci 2005;46(11):4295-301
   PubMed Web of Science ®Google Scholar
• Doganay S, Evereklioglu C, Er H, et al.Comparison of serum NO. TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 2007;16(2):163-70
   Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 103(12):1796-806
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33(11):2399-405
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116(11):2175-81; e1
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120(10):2013-22
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658-65
   PubMed Web of Science ®Google Scholar
• Semeraro F, Morescalchi F, Duse S, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opin Drug Saf 2014;13(6):785-802
   PubMed Web of Science ®Google Scholar
• Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 2012;12(10):1299-313
   PubMed Web of Science ®Google Scholar
• Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002;47(Suppl 1):S203-18
   PubMed Web of Science ®Google Scholar
• Schoenberger SD, Kim SJ, Shah R, et al. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. JAMA Ophthalmol 2014;132(1):32-7
   Web of Science ®Google Scholar
• Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res 1999;18(2):79-82
   PubMed Web of Science ®Google Scholar
• Maldonado RM, Vianna RNG, Cardoso GP, et al. Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res 2011;36(8):768-73
   PubMed Web of Science ®Google Scholar
• Reis A, Do CA, Vianna RNG, et al. [Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation]. Arq Bras Oftalmol 2010;73(4):338-42
   PubMed Web of Science ®Google Scholar
• Soheilian M, Karimi S, Ramezani A, et al. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010;30(3):509-15
   PubMed Web of Science ®Google Scholar
• Elbendary AM, Shahin MM. Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 2011;31(10):2058-64
   PubMed Web of Science ®Google Scholar
• Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 2012;6:1259-69
   PubMedGoogle Scholar
• Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol 2008;2(4):689-92
   PubMedGoogle Scholar
• Hariprasad SM, Callanan D, Gainey S, et al. Cystoid and diabetic macular edema treated with nepafenac 0.1%. J Ocul Pharmacol Ther 2007;23(6):585-90
   PubMed Web of Science ®Google Scholar
• Shimura M, Yasuda K. Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. Br J Ophthalmol 2015;99(2):215-19
   PubMed Web of Science ®Google Scholar
• Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50(3):1025-32
   PubMed Web of Science ®Google Scholar
• Tang T-C, Poon R-T, Lau C-P, et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005;11(13):1896-902
   PubMed Web of Science ®Google Scholar
• Dai Y, Zhang X, Peng Y, et al. The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol Oncol 2005;97(1):96-103
   PubMed Web of Science ®Google Scholar
• Soumaoro LT, Uetake H, Higuchi T, et al. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10(24):8465-71
   PubMed Web of Science ®Google Scholar
• Guadagni F, Ferroni P, Palmirotta R, et al. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res 2007;27(5A):3147-62
   PubMed Web of Science ®Google Scholar
• Figueiredo A, Caissie AL, Callejo SA, et al. Cyclooxygenase-2 expression in uveal melanoma: novel classification of mixed-cell-type tumours. Can J Ophthalmol 2003;38(5):352-6
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60(5):1306-11
   PubMed Web of Science ®Google Scholar
• Kojima M, Morisaki T, Uchiyama A, et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 2001;8(5):458-65
   PubMed Web of Science ®Google Scholar
• Yao M, Zhou W, Sangha S, et al. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11(4):1618-28
   PubMed Web of Science ®Google Scholar
• Abou-Issa H, Alshafie G. Celecoxib: a novel treatment for lung cancer. Expert Rev Anticancer Ther 2004;4(5):725-34
   PubMedGoogle Scholar
• De Souza Filho JP, Correa ZMS, Marshall JC, et al. The effect of a selective cyclooxygenase-2 (COX-2) inhibitor on the proliferation rate of retinoblastoma cell lines. Eye (Lond) 2006;20(5):598-601
   PubMed Web of Science ®Google Scholar
• Marshall J-CA, Fernandes BF, Di Cesare S, et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis 2007;28(9):2053-8
   PubMed Web of Science ®Google Scholar
• Mäkitie T, Summanen P, Tarkkanen A, et al. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42(7):1414-21
   PubMed Web of Science ®Google Scholar
• Jager MJ, Ly LV, El Filali M, et al. Macrophages in uveal melanoma and in experimental ocular tumor models: Friends or foes? Prog Retin Eye Res 2011;30(2):129-46
   PubMed Web of Science ®Google Scholar
• Davis TW, Hunter N, Trifan OC, et al. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol 2003;26(4):S58-61
   PubMed Web of Science ®Google Scholar
• Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 2003;95(19):1440-52
   PubMed Web of Science ®Google Scholar
• Klaassen I, Van Noorden CJF, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res 2013;34:19-48
   PubMed Web of Science ®Google Scholar
• Dunne JA, Jacobs N, Morrison A, et al. Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol 1985;69(2):120-5
   PubMed Web of Science ®Google Scholar
• Young BJ, Cunningham WF, Akingbehin T. Double-masked controlled clinical trial of 5% tolmetin versus 0.5% prednisolone versus 0.9% saline in acute endogenous nongranulomatous anterior uveitis. Br J Ophthalmol 1982;66(6):389-91
   PubMed Web of Science ®Google Scholar
• Rankin AJ, Khrone SG, Stiles J. Evaluation of four drugs for inhibition of paracentesis-induced blood-aqueous humor barrier breakdown in cats. Am J Vet Res 2011;72(6):826-32
   PubMed Web of Science ®Google Scholar
• Olson NY, Lindsley CB, Godfrey WA. Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child 1960;142(12):1289-92
   Google Scholar
• Prieto JF, Dios E, Gutierrez JM, et al. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul Immunol Inflamm 2001;9(2):93-102
   PubMed Web of Science ®Google Scholar
• Bucolo C, Marrazzo G, Platania CBM, et al. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol 2014;66(7):954-60
   PubMed Web of Science ®Google Scholar
• Lobo IB, Hoult JR. II and III extracellular phospholipases A2: selective inhibition of group II enzymes by indomethacin but not other NSAIDs. Agents Actions 1994;41:111-13
   PubMedGoogle Scholar
• Lupo G, et al. Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies. Biochem Pharmacol 2013;86:1603-13
   PubMed Web of Science ®Google Scholar
• Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992;36:259-84
   PubMed Web of Science ®Google Scholar
• Wilson FM. Adverse external ocular effects of topical ophthalmic therapy: An epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc 1983;81:854-965
   PubMedGoogle Scholar
• Shimazaki J, Saito H, Yang HY, et al. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Cornea 1995;14(6):623-7
   PubMed Web of Science ®Google Scholar
• NSAID Adverse Reaction Report. (Press release): American Society of Cataract and Refractive Surgery. 1999
   Google Scholar
• NSAID Update. (Press release): American Society of Cataract and Refractive Surgery, American Society of Ophthalmic Administrators. 1999
   Google Scholar
• Hargrave SL, Jung JC, Fini ME, et al. Possible role of the vitamin E solubilizer in topical diclofenac on matrix metalloproteinase expression in corneal melting: an analysis of postoperative keratolysis. Ophthalmology 2002;109(2):343-50
   PubMed Web of Science ®Google Scholar